Skip to content
Review Open access

The host matters: Integrating resting energy expenditure into personalized medicine beyond tumor-centered approaches.

Sep 2026 · Clinical Nutrition ESPEN · pp. 105088 · 0 citations
Medicine

TL;DR

A personalized medicine approach integrating REE, given its growing evidence for prognostic and clinical utility, with nutritional support, adapted physical activity, and targeted anti-cachexia therapies, all coordinated by the oncologist, represents a promising path forward.

Abstract

Background

AND

Aims

Malnutrition is one of the most frequent and significant complications of cancer, driven by cachexia, a multifactorial metabolic syndrome characterized by systemic inflammation, anorexia, and progressive loss of muscle mass and function. It affects up to 80% of patients with cancer and contributes to treatment intolerance, reduced quality of life, and poor survival. Despite its major nutritional and prognostic burden, cachexia-related malnutrition remains insufficiently characterized and inadequately managed in routine oncology practice.

Methods

We conducted a narrative review of the current literature on the pathophysiology of cancer cachexia, the role of resting energy expenditure (REE) as an emerging host depending metabolic biomarker, nutritional recommendations, and therapeutic strategies targeting cachexia, such as adapted physical activity and anti-cachexia pharmacological agents.

Results

Cancer cachexia results from tumor-host metabolic interactions involving pro-inflammatory cytokines, skeletal muscle proteolysis, adipose tissue browning, and tumor-derived endocrine mediators such as GDF-15. REE measurement by indirect calorimetry identifies hypermetabolism as an independent prognostic factor across cancer types and treatments, including immunotherapy. Current nutritional recommendations lack granularity and do not account for individual metabolic phenotypes, cancer type, disease stage, or therapeutic modality. Emerging therapies, including GDF-15 inhibitors, offer promising but still incomplete responses to cachexia-related wasting.

Conclusion

Addressing cancer cachexia requires extension of tumor-centered precision oncology to the management of the tumor-bearing host. A personalized medicine approach integrating REE, given its growing evidence for prognostic and clinical utility, with nutritional support, adapted physical activity, and targeted anti-cachexia therapies, all coordinated by the oncologist, represents a promising path forward.

Read PDF

Similar papers

Review Open access Oct 2026

Beyond reduced intake: tumor metabolism and immune dysregulation drive cancer-related malnutrition in head and neck squamous cell carcinoma (HNSCC)

Cancer-related malnutrition is highly prevalent in patients with head and neck squamous cell carcinoma (HNSCC) and represents a major determinant of treatment tolerance, quality of life, and survival. Although traditionally attributed to reduced oral intake caused by dysphagia, mucositis, and treatment-related toxicity...

V. Zurlo, Arianna Piccirillo, M. L. Marciano et al. · 0 citations
Review Oct 2026

Pancreatic Cancer Cachexia: Integrating Mechanistic Insights With Clinical Management.

Cachexia is a multifactorial syndrome characterized by systemic inflammation, weight loss, and muscle wasting, affecting over 80% of patients with pancreatic cancer. It decreases treatment tolerance, quality of life, and survival. Yet, despite its well-recognized detrimental impact, cachexia remains underdiagnosed and...

Lyndon Huang, Valeria Impedovo, Stefano Tiziani et al. · 0 citations
Review Sep 2026

[Sarcopenia in gastrointestinal oncology: Diagnostic criteria, clinical implications and management].

Sarcopenia is defined as a loss of muscle mass and strength. It represents a frequent and multifactorial complication in patients with gastrointestinal cancers, resulting from the combined effects of malnutrition, chronic inflammation, metabolic alterations, and reduced physical activity level. Its assessment relies on...

Géraldine M. Camilleri, Eléa Janvier, F. Pigneur et al. · 0 citations
Review Open access Aug 2026

Cancer Cachexia Research and Drug Development: Lessons from Failures and the Promise of Immunomodulation

This review summarizes the progression of cachexia research, highlighting key findings involving inflammatory cytokines, proteolytic pathways, mitochondrial dysfunction, and immune dysregulation, and novel immunomodulatory strategies, including R-ketorolac, which may restore immune homeostasis and target the root cause...

Ling-Bing Zhang, Jeffrey A. Norton · 0 citations
Review Open access Sep 2026

Cancer Cachexia in Advanced Renal Cell Carcinoma: From Molecular Mechanisms to Prognostic Assessment

Cancer cachexia is a multifactorial metabolic syndrome characterized by progressive skeletal muscle loss, affecting 30–60% of patients with advanced renal cell carcinoma (RCC). It significantly impacts treatment tolerance, quality of life, and prognosis, yet its diagnosis and management remain challenging due to fragme...

Yu-Shuang Cui, Yu-Dong Cao, Chen Lin et al. · 0 citations
Review Aug 2026

The gut microbiota in cachexia: master regulator of neuro-immune-metabolic cross-talk.

This review systematically delineates the alterations in gut microbiota dysbiosis across various etiologies of cachexia and the functional roles of their related metabolites, and summarizes the mechanisms by which the gut microbiota regulates cachexia through the nervous system.

Ke Gao, Wen-Jin Xi, Yonghua Lei et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.